Sales in Turkey continue to drive Zentiva's sales
This article was originally published in Scrip
Sales of Eczacibasi-Zentiva, the Czech company's subsidiary in Turkey, increased more than 3.5-fold to CK2.3 billion ($117.1 million) in the first nine months of this year and continued to drive the business. Zentivabelieves that the Turkish market, which has become its second-largest market, will substantially contribute to its growth over the next few years.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.